Russian Heart Failure Journal 2009year Improvement of drug treatment chronic heart failure in XXI century: progress and problems


To access this material please log in or register

Register Authorize
2009/

Improvement of drug treatment chronic heart failure in XXI century: progress and problems

Gilyarevskiy S.R.

Keywords: XXI century, progress of therapy, drug therapy, problems of treatment, CHF

DOI:

The review reflects the most significant events of data-based cardiology in the area of drug treatment of chronic heart failure
  1. Jaarsma T, Beattie JM, Ryder M et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009; 11 (5):433–443.
  2. Goodlin SJ. Palliative Care in Congestive Heart Failure. J Am Coll Cardiol. 2009; 54 (5):386–396.
  3. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314 (24):1547–1552.
  4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23):1429–1435.
  5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327 (10):685–691.
  6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325 (5):293–302.
  7. Pfeffer MA, Braunwald E, Moye LA et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992; 327 (10):669–677.
  8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342 (8875):821–828.
  9. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995; 333 (25):1670–1676.
  10. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353 (9169):2001–2007.
  11. CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet. 1999; 353 (9146):9–13.
  12. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341 (10):709–717.
  13. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. (COPERNICUS). N Engl J Med. 2001; 344 (22):1651–1658.
  14. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail. 2001; 3 (3):351–357.
  15. Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002; 23 (11):877–885.
  16. Pitt B, Segal R, Martinez FA et al; on behalf of the ELITE investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Eldery Study, ELITE). Lancet. 1997; 349 (9054):747–752.
  17. Pitt B, Poole-Wilson PA, Segal R et al on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355 (9215):1582–1587.
  18. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345 (23):1667–1675.
  19. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Com­mittees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362 (9386):759–766.
  20. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348 (14):1309–1321.
  21. Katwa LC, Tyagi SC, Campbell SE et al. Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. Int J Biochem Cell Biol. 1996; 28 (7):807–821.
  22. Borges JC, Silva JA Jr, Gomes MA et al. Tonin in rat heart with experimental hypertrophy. Am J Physiol Heart Circ Physiol. 2003; 284 (6):H2263–2268.
  23. Birkenhäger WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet. 2007; 370 (9583):195–196.
  24. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006; 368 (9545):1449–1456.
  25. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003; 308 (4):698–705.
  26. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002; 39 (1):E1–8.
  27. McMurray JJ, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1 (1):17–24.
  28. Latini R, Masson S, Anand I et al; for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation. 2002; 106 (19):2454–2458.
  29. Cohn JN, Tam SW, Anand IS et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007; 13 (5):331–339.
  30. Latini R, Masson S, Anand I et al; for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation. 2002; 106 (19):2454–2458.
  31. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25 (4):292–299.
  32. Latini R, Masson S, Wong M et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006; 119 (1):70.e23–30.
  33. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007; 49 (16):1733–1739.
  34. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000; 101 (4):378–384.
  35. Diaz A, Bourassa M, Guertin M, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26 (10):967–974.
  36. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR / trandolapril STudy (INVEST). Eur Heart J. 2008; 29 (10):1327–1334.
  37. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 (9641):807–816.
  38. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150 (11):784–794.
  39. Yamagishi K, Nettleton JA, Folsom AR; ARIC Study Investigators. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2008; 156 (5):965–974.
  40. Yamagishi K, Iso H, Date C et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. 2008; 52 (12):988–996.
  41. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 (9645):1223–1230.
  42. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354 (9177):447–455.
  43. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet. 2008; 372 (9645):1195–1196.
  44. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002; 39 (10):1567–1573.
  45. Bohm M, Hjalmarson A, Kjekshus J et al. Heart failure and statins – why do we need a clinical trial? Z Kardiol. 2005; 94 (4):223–230.
  46. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005; 7 (6):1059–1069.
  47. Cleland JG, Loh H, Windram J et al. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J. 2006; 27 (6):641–643.
  48. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002; 8 (4):216–224.
  49. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003; 42 (11):1933–1940.
  50. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356 (9233):930–933.
  51. Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000; 102 (6):611–616.
  52. Orn S, Cleland JG, Romo M et al. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med. 2005; 118 (7):752–758.
  53. Krum H, Latini R, Maggioni AP et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007; 119 (1):48–53.
  54. Go AS, Lee WY, Yang J et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006; 296 (17):2105–2111.
  55. van der Harst P, Voors AA, van Gilst WH et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med. 2006; 3 (8):e333.
  56. Martin J. H, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007; 113:119–127.
  57. Krum H, Ashton E, Reid C et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007; 13 (1):1–7.
  58. Taylor AL, Ziesche S, Yancy C et al. For the A-HeFT Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351 (20):2049–2057.
  59. Stiles S. Dr Jay N Cohn and A-HeFT: Persistence rewarded. Available at: www.theheart.org Nov 5, 2004.
  60. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359 (23):2456–2467.
  61. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27 (19):2338–2345.

To access this material please log in or register

Register Authorize
Ru En